GoodRx Holdings, Inc. (GDRX) 股票分析

公司概述

GoodRx Holdings, Inc. operates primarily within the United States by providing information and tools that facilitate price comparison for prescription drugs, enabling consumers to reduce their medication costs. The company functions within the Healthcare sector, specifically in the Health Information Services industry, which implies a focus on data aggregation and digital platform services rather than direct pharmaceutical manufacturing or retail sales. With a market capitalization of $739.96M and annual revenue of $796.85M, the entity demonstrates a substantial operational footprint supported by a workforce of 697 employees. These valuation and revenue figures suggest that the company holds a significant position in the digital health space, commanding a market value that reflects its role in connecting consumers with affordable medication options through a curated, geographically relevant platform.

财务健康

The company reported a trailing twelve-month revenue of $796.85M alongside a net income of $30.44M and an EBITDA of $122.31M, revealing a distinct gap between top-line growth and bottom-line profitability that highlights a substantial cost structure including operating expenses and taxes. Despite generating significant EBITDA, the net income figure indicates that non-operating costs or interest obligations absorb a considerable portion of the earnings before tax. The business maintains a gross margin of 92.8%, which is exceptionally high for the sector and suggests strong pricing power or low direct fulfillment costs relative to sales. Operating margins stand at 19.0%, reflecting the efficiency of core business operations before interest and taxes, while the profit margin of 3.8% underscores the impact of fixed costs and interest on the final bottom line. In terms of liquidity and leverage, GoodRx holds $261.82M in cash against $542.81M in debt, resulting in a debt-to-equity ratio of 88.08 which characterizes a highly leveraged balance sheet. The current ratio of 2.61 indicates robust short-term liquidity, suggesting the company possesses ample current assets to cover its immediate liabilities. Return on equity is measured at 4.5% and return on assets at 4.8%, metrics that reveal a moderate level of management effectiveness in generating returns relative to the capital invested and the asset base utilized.

估值评估

Valuation metrics show a trailing P/E ratio of 24.00 contrasted with a forward P/E of 5.88, implying a stark divergence between current earnings and expected future earnings that suggests the market anticipates a significant deterioration or restructuring in profitability. The price-to-book ratio stands at 1.20, indicating that the market values the company slightly above its book value but not at a significant premium. Alternative valuation indicators include a price-to-sales ratio of 0.93 and an EV/EBITDA of 8.35, which suggest the company is trading at a reasonable multiple relative to its sales and enterprise earnings power. Regarding price volatility, the 52-week high is recorded at $5.81 and the low at $1.77, providing a trading range of $4.04 within which the current market price must be situated relative to these historical extremes. The stock exhibits a beta of 1.47, which signifies that the equity price is expected to fluctuate 47% more volatile than the broader market index, reflecting higher sensitivity to market movements.

Growth & Income

Recent performance data indicates a revenue growth rate of -1.9% year-over-year and an earnings growth rate of -9.7% year-over-year, demonstrating that earnings are contracting at a faster pace than revenue, which points to margin compression or one-off charges impacting profitability. As the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all generated earnings rather than distributing them to shareholders. This absence of dividend payouts aligns with the company's strategy of reinvesting cash flow into business operations and debt management rather than providing current income to investors. Consequently, the overall growth and income profile is characterized by negative earnings growth and zero dividend income, reflecting a capital allocation strategy focused on internal growth mechanisms and balance sheet restructuring rather than shareholder yield.